The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...
Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback